Brief: Diamyd Medical: Financial, Operational Update On Diabetes Vaccine
13/10/2020 07:59
Oct 13 (Reuters) - Diamyd Medical AB DMYDb.ST :
* SAID ON MONDAY CURRENT CASH POSITION OF ABOUT SEK 180 MLN
SUPPORTS ONGOING OPERATIONAL ACTIVITIES AND START-UP ACTIVITIES
FOR CONFIRMATORY PHASE III TRIAL WITH DIABETES VACCINE DIAMYD
* IS PURSUING POTENTIAL PARTNERSHIPS FOR FUTURE
COMMERCIALIZATION
ALONGSIDE DISCUSSIONS WITH POTENTIAL INVESTORS
* AIM OF FULLY FINANCING EXECUTION THE PHASE III PROGRAM,
MANUFACTURING PROGRAM, AND MARKET LAUNCH
* WILL DISCUSS THE PHASE III PROGRAM WITH FDA Q1 2021
* ESTABLISHING OF VACCINE MANUFACTURING FACILITY IN UMEÅ,
SWEDEN,
IS PROGRESSING
Source text for Eikon: urn:newsml:reuters.com:*:nWkr3H7lyS
Further company coverage: DMYDb.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10))